Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial cell membrane formation is critically dependent on the de novo synthesis of fatty acids via the type II fatty acid synthase (FASII) pathway. This pathway is essential for bacterial survival, as it provides the building blocks for membrane phospholipids. Key enzymes include acetyl-CoA carboxylase (AccABCD), FabH, FabB, FabF, FabG, and FabZ/FabA. The pathway is regulated by transcriptional regulators like FadR and FabR. Its structural divergence from the mammalian type I FAS makes it a promising target for antibacterial drug development. Inhibitors like platensimycin, triclosan, and isoniazid target specific enzymes within this pathway.
Inhibition of fatty acid synthesis enzymes (e.g., FabH, FabB, FabF, Acetyl-CoA carboxylase)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial Fatty Acid Synthesis Pathway (FASII).